Sun’s Ilumya Ramps Up In Skyrizi’s Shadow

 
• By Anju Ghangurde

Patient numbers and prescriptions in the US for Sun’s psoriasis therapy Ilumya are steadily on the rise, and the Indian firm said that the arrival of AbbVie’s rival Skyrizi hasn’t adversely impacted its formulary position.

Eclipse
Sun's Ilumya Sees Gradual Ramp Up In US • Source: Shutterstock

More from Business

More from Scrip